Cover Image

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

Background: To date, no oral antiviral drug has proven to be beneficial in hospitalized patients with COVID-19.Methods: In this randomized, controlled, open-label, platform trial, we randomly assigned patients ≥18 years hospitalized with COVID-19 pneumonia to receive either camostat mesylate (CM) (c...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Karolyi (Author), E. Pawelka (Author), S. Omid (Author), F. Koenig (Author), V. Kauer (Author), B. Rumpf (Author), W. Hoepler (Author), A. Kuran (Author), H. Laferl (Author), T. Seitz (Author), M. Traugott (Author), V. Rathkolb (Author), M. Mueller (Author), A. Abrahamowicz (Author), C. Schoergenhofer (Author), M. Hecking (Author), A. Assinger (Author), C. Wenisch (Author), M. Zeitlinger (Author), B. Jilma (Author), A. Zoufaly (Author)
Format: Book
Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items